Ross DM - Search Results

1

Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells.

Ross DM, Pagani IS, Shanmuganathan N, Kok CH, Seymour JF, Mills AK, Filshie RJ, Arthur CK, Dang P, Saunders VA, Braley J, Yong AS, Yeung DT, White DL, Grigg AP, Schwarer AP, Branford S, Hughes TP; Australasian Leukaemia and Lymphoma Group (ALLG). Ross DM, et al. Leukemia. 2018 Dec;32(12):2572-2579. doi: 10.1038/s41375-018-0264-0. Epub 2018 Oct 12. Leukemia. 2018. PMID: 30315232

2

Cancer treatment with kinase inhibitors: what have we learnt from imatinib?

Ross DM, Hughes TP. Ross DM, et al. Br J Cancer. 2004 Jan 12;90(1):12-9. doi: 10.1038/sj.bjc.6601507. Br J Cancer. 2004. PMID: 14710199 Free PMC article. Review.

3

Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL.

Ross DM, Branford S, Moore S, Hughes TP. Ross DM, et al. Leukemia. 2006 Apr;20(4):664-70. doi: 10.1038/sj.leu.2404139. Leukemia. 2006. PMID: 16482210

4

Current and emerging tests for the laboratory monitoring of chronic myeloid leukaemia and related disorders.

Ross DM, Hughes TP. Ross DM, et al. Pathology. 2008 Apr;40(3):231-46. doi: 10.1080/00313020801916172. Pathology. 2008. PMID: 18428043 Review.

5

How complete is "complete" molecular response in imatinib-treated chronic myeloid leukemia?

Ross DM, Hughes TP. Ross DM, et al. Leuk Lymphoma. 2008 Jul;49(7):1230-1. doi: 10.1080/10428190802158461. Leuk Lymphoma. 2008. PMID: 18604711 No abstract available.

6

Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: implications for defining sensitivity in minimal residual disease.

Ross DM, Watkins DB, Hughes TP, Branford S. Ross DM, et al. Clin Chem. 2008 Sep;54(9):1568-71. doi: 10.1373/clinchem.2008.105916. Epub 2008 Jul 18. Clin Chem. 2008. PMID: 18641042

7

Reply to 'What do we mean by sensitivity when we talk about detecting minimal residual disease?' by Steinbach and Debatin.

Ross DM, Branford S, Melo JV, Hughes TP. Ross DM, et al. Leukemia. 2009 Apr;23(4):819-20; author reply 820. doi: 10.1038/leu.2008.330. Epub 2008 Nov 20. Leukemia. 2009. PMID: 19020541 No abstract available.

8

Genomic translocation breakpoint sequences are conserved in BCR-ABL1 cell lines despite the presence of amplification.

Ross DM, Schafranek L, Hughes TP, Nicola M, Branford S, Score J. Ross DM, et al. Cancer Genet Cytogenet. 2009 Mar;189(2):138-9. doi: 10.1016/j.cancergencyto.2008.10.010. Cancer Genet Cytogenet. 2009. PMID: 19215797 No abstract available.

9

Extramedullary relapse of chronic myeloid leukemia in blast crisis: more questions than answers.

Ross DM. Ross DM. Leuk Lymphoma. 2009 Apr;50(4):517-8. doi: 10.1080/10428190902777483. Leuk Lymphoma. 2009. PMID: 19373644 No abstract available.

10

Rapid isolation of translocation breakpoints in chronic myeloid and acute promyelocytic leukaemia.

Bartley PA, Martin-Harris MH, Budgen BJ, Ross DM, Morley AA. Bartley PA, et al. Among authors: ross dm. Br J Haematol. 2010 Apr;149(2):231-6. doi: 10.1111/j.1365-2141.2009.08071.x. Epub 2010 Jan 11. Br J Haematol. 2010. PMID: 20067557 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

199 results

Search Page

Filters